Abstract
When recombinant glycoproteins for therapeutic use are to be produced on an industrial scale, there is a crucial need for technologies that can engineer fast-growing stable cells secreting the protein drug at a high rate and with a defined and safe glycosylation profile. Current cell lines approved for drug production are essentially from rodent origin. Their glycosylation machinery often adds undesired carbohydrate determinants which may alter protein folding, induce immunogenicity, and reduce circulatory life span of the drug. Notably, sialic acid as N-acetylneuraminic acid is not efficiently added in most mammalian cells and the 6-linkage is missing in rodent cells. Engineering cells with the various enzymatic activities required for sialic acid transfer has not yet succeeded in providing a human-like pattern of glycoforms to protein drugs. To date, there is a need for engineering animal cells and get highly sialylated products that resemble as closely as possible to human proteins. We have designed ST6Gal minigenes to optimize the ST6GalI sialyltransferase activity and used them to engineer ST6(+)CHO cells. When stably transfected in cells expressing a protein of interest or not, these constructs have proven to equip cell clones with efficient transfer activity of 6-linked sialic acid. In this chapter, we describe a methodology for generating healthy stable adherent clones with hypersialylation activity and high secretion rate.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wacker C, Berger CN, Girard P, Meier R (2011) Glycosylation profiles of therapeutic antibody pharmaceuticals. Eur J Pharm Biopharm 79:503–507
Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL et al (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A 95:11751–11756
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109–1117
Noguchi A, Mukuria CJ, Suzuki E, Naiki M (1995) Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem 117:59–62
Zhu A, Hurst R (2002) Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9:376–381
Byres E, Paton AW, Paton JC, Lofling JC, Smith DF, Wilce MC et al (2008) Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 456:648–652
Hedlund M, Padler-Karavani V, Varki NM, Varki A (2008) Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A 105:18936–18941
Lee EU, Roth J, Paulson JC (1989) Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase. J Biol Chem 264:13848–13855
Morell AG, Gregoriadis G, Scheinberg IH, Hickman J, Ashwell G (1971) The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246:1461–1467
Briggs DW, Fisher JW, George WJ (1974) Hepatic clearance of intact and desialylated erythropoietin. Am J Physiol 227:1385–1388
Bork K, Horstkorte R, Weidemann W (2009) Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci 98:3499–3508
Bork K, Reutter W, Weidemann W, Horstkorte R (2007) Enhanced sialylation of EPO by overexpression of UDP-GlcNAc 2-epimerase/ManAc kinase containing a sialuria mutation in CHO cells. FEBS Lett 581:4195–4198
Jeong YT, Choi O, Lim HR, Son YD, Kim HJ, Kim JH (2008) Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expression. J Microbiol Biotechnol 18:1945–1952
Son YD, Jeong YT, Park SY, Kim JH (2011) Enhanced sialylation of recombinant human erythropoietin in Chinese hamster ovary cells by combinatorial engineering of selected genes. Glycobiology 21:1019–1028
Fukuta K, Yokomatsu T, Abe R, Asanagi M, Makino T (2000) Genetic engineering of CHO cells producing human interferon-gamma by transfection of sialyltransferases. Glycoconj J 17:895–904
Ferrari J, Gunson J, Lofgren J, Krummen L, Warner TG (1998) Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid. Biotechnol Bioeng 60:589–595
Minch SL, Kallio PT, Bailey JE (1995) Tissue plasminogen activator coexpressed in Chinese hamster ovary cells with alpha(2,6)-sialyltransferase contains NeuAc alpha(2,6)Gal beta(1,4)Glc-N-AcR linkages. Biotechnol Prog 11:348–351
Bragonzi A, Distefano G, Buckberry LD, Acerbis G, Foglieni C, Lamotte D et al (2000) A new Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochim Biophys Acta 1474:273–282
Damiani R, Oliveira JE, Vorauer-Uhl K, Peroni CN, Vianna EG, Bartolini P et al (2009) Stable expression of a human-like sialylated recombinant thyrotropin in a Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase. Protein Expr Purif 67:7–14
Zhang X, Lok SH, Kon OL (1998) Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity. Biochim Biophys Acta 1425:441–452
Jassal R, Jenkins N, Charlwood J, Camilleri P, Jefferis R, Lund J (2001) Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase. Biochem Biophys Res Commun 286:243–249
Legaigneur P, Breton C, El Battari A, Guillemot JC, Auge C, Malissard M et al (2001) Exploring the acceptor substrate recognition of the human beta-galactoside alpha 2,6-sialyltransferase. J Biol Chem 276:21608–21617
Paulson JC, Colley KJ (1989) Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J Biol Chem 264:17615–17618
Datta AK, Paulson JC (1995) The sialyltransferase “sialylmotif” participates in binding the donor substrate CMP-NeuAc. J Biol Chem 270:1497–1500
Datta AK, Paulson JC (1997) Sialylmotifs of sialyltransferases. Indian J Biochem Biophys 34:157–165
Datta AK, Chammas R, Paulson JC (2001) Conserved cysteines in the sialyltransferase sialylmotifs form an essential disulfide bond. J Biol Chem 276:15200–15207
Angata K, Yen TY, El Battari A, Macher BA, Fukuda M (2001) Unique disulfide bond structures found in ST8Sia IV polysialyltransferase are required for its activity. J Biol Chem 276:15369–15377
Tsuji S, Datta AK, Paulson JC (1996) Systematic nomenclature for sialyltransferases. Glycobiology 6:v–vii
Jeanneau C, Chazalet V, Auge C, Soumpasis DM, Harduin-Lepers A, Delannoy P et al (2004) Structure-function analysis of the human sialyltransferase ST3Gal I: role of n-glycosylation and a novel conserved sialylmotif. J Biol Chem 279:13461–13468
Datta AK, Sinha A, Paulson JC (1998) Mutation of the sialyltransferase S-sialylmotif alters the kinetics of the donor and acceptor substrates. J Biol Chem 273:9608–9614
Fenteany FH, Colley KJ (2005) Multiple signals are required for alpha2,6-sialyltransferase (ST6Gal I) oligomerization and Golgi localization. J Biol Chem 280:5423–5429
Acknowledgment
The “Preparation and Uses of Gene Sequences encoding Chimerical Glycosyltransferases with Optimized Glycosylation Activity” has been patented as EP2019864 (C. Ronin and G. Guiraudie-Capraz, inv).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Maï, N.E., Donadio-Andréi, S., Iss, C., Calabro, V., Ronin, C. (2013). Engineering a Human-Like Glycosylation to Produce Therapeutic Glycoproteins Based on 6-Linked Sialylation in CHO Cells. In: Beck, A. (eds) Glycosylation Engineering of Biopharmaceuticals. Methods in Molecular Biology, vol 988. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-327-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-62703-327-5_2
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-326-8
Online ISBN: 978-1-62703-327-5
eBook Packages: Springer Protocols